Effects of 3 Years of Hormone Therapy, Raloxifene, and Alendronate on Mammographic Breast Density in Postmenopausal Korean Women / 대한폐경학회지
The Journal of Korean Society of Menopause
;
: 94-101, 2011.
Artículo
en Coreano
| WPRIM
| ID: wpr-172083
ABSTRACT
OBJECTIVES:
Breast density is an independent risk factor for the development of invasive breast cancer. We conducted this study to evaluate the effects of 3 years of hormone therapy, raloxifene, and alendronate on mammographic breast density in postmenopausal Korean women.METHODS:
We studied 127 postmenopausal women who had visited the Department of Obstetrics and Gynecology of Inje University Sanggye Paik Hospital between January 2000 and June 2010. These patients were divided into the following 5 groups alendronate (n = 26); raloxifene (n = 18); estrogen therapy (ET; n = 43); continuous estrogen-progesterone therapy (EPT; n = 20); and cyclic EPT (n = 20). The Breast Image Reporting and Data System (BI-RADS) composition grade 1, 2, and 3 years after treatment was compared with the BI-RADS composition grade at baseline.RESULTS:
The BI-RADS grade decreased significantly in the raloxifene group at 1 year (P = 0.04). The BI-RADS grade increased significantly in the ET group at 3 years (P = 0.03), in the continuous EPT at 1, 2, and 3 years (P = 0.01, < 0.001, < 0.001, respectively), and in the cyclic EPT group at 2 and 3 years (P = 0.04 and 0.02, respectively). Although not statistically significant, a decrease in the BI-RADS grade occurred in the alendronate group at 1, 2, and 3 years (P = 0.08, 0.1, and 0.1, respectively).CONCLUSION:
This study showed that there was significant decrease in mammographic breast density at 1 year in the raloxifene group and a decreasing trend in the alendronate group, whereas there was significant increase in the ET and EPT groups. To determine the effect of raloxifene and alendronate on breast density, larger prospective studies are needed.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Mama
/
Neoplasias de la Mama
/
Menopausia
/
Sistemas de Información
/
Factores de Riesgo
/
Alendronato
/
Clorhidrato de Raloxifeno
/
Estrógenos
/
Ginecología
/
Obstetricia
Tipo de estudio:
Estudio de etiología
/
Estudio observacional
/
Factores de riesgo
Límite:
Femenino
/
Humanos
Idioma:
Coreano
Revista:
The Journal of Korean Society of Menopause
Año:
2011
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS